Meeting
2022 ASCO Genitourinary Cancers Symposium
Long-term follow-up of intravesical gemcitabine and docetaxel as rescue therapy for nonmuscle-invasive bladder cancer.
Authors
Phani T. Chevuru
The University of Iowa Carver College of Medicine, Iowa City, IA
Phani T. Chevuru , Ian Mitchell McElree , Alexander C. Martin , Jordan Richards , Sarah L. Mott , Paul T. Gellhaus , Kenneth G. Nepple , Ryan L. Steinberg , Michael A. O'Donnell , Vignesh T. Packiam
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Other
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 573)
DOI
10.1200/JCO.2022.40.6_suppl.573
Abstract #
573
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Intravesical gemcitabine and docetaxel in the treatment of BCG-naïve non–muscle invasive urothelial carcinoma of the bladder: Updates from a phase 2 trial.
First Author: Sunil H. Patel
Poster
2022 ASCO Genitourinary Cancers Symposium
Sequential intravesical gemcitabine and docetaxel for BCG-naïve high-risk nonmuscle-invasive bladder cancer.
First Author: Ian Mitchell McElree
Poster
2019 Genitourinary Cancers Symposium
Sequential intravesical gemcitabine and docetaxel in the treatment of BCG-naive patients with non-muscle invasive bladder cancer.
First Author: Lewis Thomas
Poster
2017 ASCO Annual Meeting
Oncological outcomes of intravesical gemcitabine and docetaxel for select patients with high grade recurrent NMIBC.
First Author: Niv Milbar